Report Highlights Research Needed To Foster Generic Drug Development

October 2017

Pharmaceutical News

Country of origin: USA

The US Food and Drug Administration (FDA) recently issued the ?Critical Path Opportunities for Generic Drugs? report identifying many of the unanswered scientific questions that impede the development of generic versions of commonly used drugs.

The report is part of FDA?s Critical Path Initiative, established in 2004 to discern what challenges exist in moving a promising drug, biologic or device along the critical path from discovery, or proof of concept, to a marketable product.

Solving these challenges will require the expertise and input of many groups, including scientists from universities, patient groups, government, industry, associations and other private organisations.

?This report pinpoints the barriers that are limiting the availability of additional generic drug options,? said Gary Buehler, R.Ph., director, FDA?s Office of Generic Drugs. ?We hope these findings will encourage research collaboration, lower these barriers and accelerate access to safe and effective generic drugs.?

Before they can be approved, generic drugs must have the same active ingredient, dosage form, strength, and conditions of use as the brand name drug. The drugs must also be absorbed at the same rate and in the same amount, a concept known as bioequivalence.

While straightforward tests of blood plasma levels are sufficient to demonstrate bioequivalence for most generic drug candidates, these common tests generally are not appropriate for certain drugs, including asthma inhalers, nasal sprays, and topical skin applications such as anti-fungal creams. As a result, few generic versions are available in these product categories, resulting in less competition and higher prices.

For example, generic drug products that contain the ozone-depleting substance chlorofluorocarbon will be withdrawn from the market after 2008.
The new report will help ensure FDA has an adequate scientific basis to review inhaler applications that use an alternative, hydrofluoroalkane.

The report also calls for research on new bioequivalence methods tailor-made for each challenging drug class. These include lung function tests and molecular level imaging for inhalation drugs; particle size distribution tests for nasal sprays; and methods for direct measurement of drug delivered to the skin.

In addition, the report highlights possible research projects that might lead to new modeling and simulation tools for drug absorption, drug release and other drug development issues and to alternative methods for seeking waivers from clinical bioequivalence studies.

During 2006 FDA issued the Critical Path Opportunities Report listing 76 specific scientific projects that, if undertaken, would help modernise the Critical Path sciences. This companion document focuses more narrowly on the scientific challenges unique to the development of generic drugs.

Resources

Medicines for Children: practical and reliable information for parents and carers September 2018 The vision of Medicines for Children is that any parent, wherever they are, have information on their child’s medicines...
Anticoagulation Manager September 2018 The Anticoagulation Manager is a mobile application developed through the collaborative efforts of the CDC and the Georgia...
Clinical Pain Advisor September 2018 Clinical Pain Advisor is a free, simple to use, medical app that offers pain medicine healthcare professionals a...
Anticoagulation Manager June 2018 The Anticoagulation Manager is a mobile application developed through the collaborative efforts of the CDC and the Georgia...
Anticoagulation Manager May 2018 The Anticoagulation Manager is a mobile application developed through the collaborative efforts of the CDC and the Georgia...
Start Smart – Then Focus April 2018 The Department of Health has published new guidance Start Smart - Then Focus which will help hospital prescribers ensure...
Website on the dangers of counterfeit drugs March 2018 Amid increased concern over the growing epidemic of counterfeit drugs, the National Associations of Boards of Pharmacy has...
Better access to medicine safety data March 2018 Patients and researchers are able to look at data on the safety of different medicines. Part of a series of measures to...
ACEP Toxicology February 2018 The Antidote app is a succinct resource designed for quick access to indications and dosing regimens for a variety of...
The Drugs & Bugs app January 2018 The Drugs & Bugs app by Monthly Prescribing Reference (MPR) is an essential resource for allied healthcare professionals,...
Search by Keyword